ABSTRACT
Background: Chronic kidney disease (CKD) poses a significant health burden globally, often associated with complications such as increased urinary albumin excretion, which is a marker of kidney damage and cardiovascular risk. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, has shown promising results in reducing albuminuria in patients with type 2 diabetes. However, its efficacy in patients with CKD remains to be fully elucidated.
Aim: This retrospective study aimed to evaluate the impact of dapagliflozin treatment on urinary albumin excretion in patients diagnosed with CKD.
Methods: Medical records of patients diagnosed with CKD who were prescribed dapagliflozin were retrospectively analyzed. Patients with baseline and follow-up measurements of urinary albumin excretion were included in the study. Changes in urinary albumin excretion from baseline to follow-up were assessed.
Results: A total of 120 patients with CKD met the inclusion criteria and were included in the analysis. The mean duration of dapagliflozin treatment was February 2023 to January 2024. Following treatment initiation, a statistically significant reduction in urinary albumin excretion was observed in 67% of patients (p < 0.05).
Conclusion: Our retrospective analysis suggests that dapagliflozin may have a beneficial effect on reducing urinary albumin excretion in patients with CKD. These findings warrant further investigation through prospective randomized controlled trials to confirm the efficacy and safety of dapagliflozin in this patient population.
Keywords: Dapagliflozin, chronic kidney disease, urinary albumin excretion, sodium-glucose co-transporter 2 inhibitors, retrospective analysis.